Document Detail


Reversing neuropathic deficits.
MedLine Citation:
PMID:  22548616     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
This is a brief review of several novel strategies for therapeutic approaches to axonal damage in peripheral neuropathies. Although not comprehensive, the review addresses the challenges in axonal regrowth, newly identified roadblocks to regeneration and the concept of collateral reinnervation to restore lost neurological function.
Authors:
Douglas W Zochodne
Related Documents :
20177486 - Persistently erected penis in a child for 6 months: a management dilemma.
23765916 - A radiation-induced meningioma "cures" a complex dural arteriovenous fistula.
15179516 - Two cases of left-sided gastroschisis: review of the literature.
25250446 - A new species and new records of gripopterygidae (plecoptera) from the serra dos orgão...
23454326 - The ethnic custom of tooth adornment in rural bhutan: report of a case.
20213916 - Efficacy and safety of topical tazarotene: a review.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of the peripheral nervous system : JPNS     Volume:  17 Suppl 2     ISSN:  1529-8027     ISO Abbreviation:  J. Peripher. Nerv. Syst.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-05-02     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9704532     Medline TA:  J Peripher Nerv Syst     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4-9     Citation Subset:  IM    
Copyright Information:
© 2012 Peripheral Nerve Society.
Affiliation:
Department of Clinical Neurosciences, The Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Current issues in peripheral neuropathy.
Next Document:  Bioenergetics in diabetic neuropathy: what we need to know.